HSIC — Henry Schein Share Price
- $9.55bn
- $13.21bn
- $12.34bn
- 83
- 61
- 75
- 85
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 14.13 | ||
PEG Ratio (f) | 0.82 | ||
EPS Growth (f) | 20.92% | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.65 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 20.59 | ||
Price to Sales | 0.77 | ||
EV to EBITDA | 15.37 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 7.55% | ||
Return on Equity | 11.01% | ||
Operating Margin | 4.74% |
Financial Summary
Year End 30th Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 9,985.8 | 10,119.14 | 12,401.02 | 12,647 | 12,339 | 13,355.26 | 14,027.32 | 5.55% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +49.23 | -34.22 | +44.51 | +7.05 | -19.25 | +29.57 | +10.2 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. The Company operates through two segments: health care distribution, and technology and value-added services. The health care distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment products and vitamins. The technology and value-added services segment provide software, technology and other value-added services to health care practitioners. It offers dental practice management solutions for dental and medical practitioners. It also develops solutions for the orthopedic treatment of lower extremities (foot and ankle) and upper extremities (primarily hand and wrist).
Directors
- Stanley Bergman CHM (71)
- James Breslawski PRE (67)
- Steven Paladino CFO (64)
- David Brous CEX (52)
- Brad Connett CEX (62)
- Rene Willi CEX (53)
- Lorelei McGlynn CHO (57)
- Gerald Benjamin EVP (68)
- Mark Mlotek EVP (65)
- Christopher Pendergast SVP (58)
- Kelly Murphy SVP
- Michael Ettinger SVP (59)
- Jonathan Koch SVP (46)
- James Mullins SVP (56)
- Michael Racioppi SVP (66)
- Walter Siegel OTH (61)
- Jennifer Ferrero SEC
- Philip Laskawy LED (79)
- Scott Serota DRC
- Mohamad Ali IND (50)
- Barry Alperin IND (80)
- Deborah Derby IND (57)
- Joseph Herring IND (65)
- Kurt Kuehn IND (66)
- Anne Margulies IND (65)
- Carol Raphael IND (78)
- Elizabeth Rekow IND (76)
- Bradley Sheares IND (63)
- Last Annual
- December 30th, 2023
- Last Interim
- March 30th, 2024
- Incorporated
- December 23rd, 1992
- Public Since
- November 3rd, 1995
- No. of Shareholders
- 107,000
- No. of Employees
- 25,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 128,050,943
- Address
- 135 Duryea Rd, MELVILLE, 11747
- Web
- https://www.henryschein.com/
- Phone
- +1 6318435500
- Contact
- Graham Stanley
- Auditors
- BDO USA, P.C.
Upcoming Events for HSIC
Henry Schein Inc Annual Shareholders Meeting
Henry Schein Inc at Leerink Partners Healthcare Crossroads Conference
Henry Schein Inc at Stifel Jaws & Paws Conference
Q2 2024 Henry Schein Inc Earnings Release
Q3 2024 Henry Schein Inc Earnings Release
Similar to HSIC
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
As of Today at 13:10 UTC, shares in Henry Schein are trading at $74.60. This share price information is delayed by 15 minutes.
Shares in Henry Schein last closed at $74.60 and the price had moved by -2.55% over the past 365 days. In terms of relative price strength the Henry Schein share price has underperformed the S&P500 Index by -22.97% over the past year.
The overall consensus recommendation for Henry Schein is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Henry Schein does not currently pay a dividend.
Henry Schein does not currently pay a dividend.
Henry Schein does not currently pay a dividend.
To buy shares in Henry Schein you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $74.60, shares in Henry Schein had a market capitalisation of $9.55bn.
Here are the trading details for Henry Schein:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: HSIC
Based on an overall assessment of its quality, value and momentum Henry Schein is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Henry Schein is $79.00. That is 5.9% above the last closing price of $74.60.
Analysts covering Henry Schein currently have a consensus Earnings Per Share (EPS) forecast of $5.08 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Henry Schein. Over the past six months, its share price has underperformed the S&P500 Index by -6.96%.
As of the last closing price of $74.60, shares in Henry Schein were trading +2.19% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Henry Schein PE ratio based on its reported earnings over the past 12 months is 14.13. The shares last closed at $74.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Henry Schein's management team is headed by:
- Stanley Bergman - CHM
- James Breslawski - PRE
- Steven Paladino - CFO
- David Brous - CEX
- Brad Connett - CEX
- Rene Willi - CEX
- Lorelei McGlynn - CHO
- Gerald Benjamin - EVP
- Mark Mlotek - EVP
- Christopher Pendergast - SVP
- Kelly Murphy - SVP
- Michael Ettinger - SVP
- Jonathan Koch - SVP
- James Mullins - SVP
- Michael Racioppi - SVP
- Walter Siegel - OTH
- Jennifer Ferrero - SEC
- Philip Laskawy - LED
- Scott Serota - DRC
- Mohamad Ali - IND
- Barry Alperin - IND
- Deborah Derby - IND
- Joseph Herring - IND
- Kurt Kuehn - IND
- Anne Margulies - IND
- Carol Raphael - IND
- Elizabeth Rekow - IND
- Bradley Sheares - IND